Checkpoint Inhibitor in a Melanoma Patient With Polyendocrinopathy and Gangrenous Gallbladder With a Mass

Checkpoint inhibitors are introduced as a therapy for clinical use for various cancers, and clinicians are documenting new adverse effects. This is the first case report to the best of our knowledge of a patient on checkpoint inhibitor presenting with both polyendocrinopathy and gangrenous gallbladd...

Descripción completa

Detalles Bibliográficos
Autores principales: Fernandes, Nayson L, Sodavarapu, Soujanya, Nedopil, Sukhmine, Mohapatra, Nikita, Vyas, Dinesh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2020
Materias:
General Surgery
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7381870/
https://www.ncbi.nlm.nih.gov/pubmed/32724737
http://dx.doi.org/10.7759/cureus.8786

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7381870/
https://www.ncbi.nlm.nih.gov/pubmed/32724737
http://dx.doi.org/10.7759/cureus.8786

Ejemplares similares